HK inno.N Corporation
Prices may be delayed up to 20 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 195940.KQ | 000230.KS | 003000.KS | 000640.KS | 002210.KS | 016580.KS | |
|---|---|---|---|---|---|---|
| Market cap | 1.04T | 65.20B | 380.35B | 600.98B | 104.70B | 200.18B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | — | — | — | — | — | — |
| Price/book | — | — | — | — | — | — |
| Dividend yield | 1.20% | 1.79% | 1.95% | 1.93% | — | 2.76% |
| 1-year change | −30.39% | −52.38% | +1.19% | −15.76% | +16.86% | −5.81% |
| Today | +7.01% | +0.89% | +0.39% | +1.48% | −2.20% | −0.28% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 20 min.
Latest news
All 195940.KQ news ›HK inno.N Partners with Roche Diagnostics to Enter Medical Device Market, Targeting In-Hospital Testing
HK inno.N (195940) is entering the medical device market for the first time by partnering with Roche Diagnostics Korea. The company plans to leverage its prescription drug sales network to penetrate the point-of-care diagnostics market for…
HK inno.N Earnings Outlook Cut on K-CAB Inventory Adjustment
Korea's first economic newspaper, established in 1960. Providing comprehensive coverage of Korean business, finance, technology, and economic news. HK inno.N (195940.KS) is expected to post third-quarter results below market expectations…
HK inno.N presents U.S. Phase 3 results for new drug ‘K-CAB’ in non-erosive gastroesophageal reflux disease at ACG
[by Kang, In Hyo] HK inno.N’s novel gastroesophageal reflux disease (GERD) treatment, ‘K-CAB’ (tegoprazan), met its primary and secondary endpoints in a U.S. Phase 3 trial for non-erosive GERD (NERD), significantly improving both heartburn…
HK inno.N's tegoprazan increases heartburn-free days in US phase 3 reflux trial
Patients taking HK inno.N's K-CAB (tegoprazan) had significantly more heartburn-free days and nights than those receiving placebo in a U.S. phase 3 trial involving 783 adults with non-erosive reflux disease (NERD). The trial found that…
HK inno.N's K-CAB Meets Primary Endpoints in U.S. Phase 3 Trial
Heartburn and Acid Reflux Improved in 783 U.S. Patients Symptom-Free Days Rose Significantly Over Placebo After Four Weeks Added Erosive Esophagitis Analysis Wins ACG Presidential Award HK inno.N's (195940.KS) gastroesophageal reflux…
HK inno.N obesity drug cuts teen weight up to 12% in 20-week trial in Korea
HK inno.N(195940) introduced an obesity treatment now in phase 3 in Korea that reduced body weight by more than 10% over 20 weeks in a clinical trial for adolescents. After results in adults, the possibility of improving weight and…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- en.sedaily.com1
- finance.biggo.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 2 articles, not a forecast.